ECSP088531A - Vacuna terapéutica - Google Patents

Vacuna terapéutica

Info

Publication number
ECSP088531A
ECSP088531A EC2008008531A ECSP088531A ECSP088531A EC SP088531 A ECSP088531 A EC SP088531A EC 2008008531 A EC2008008531 A EC 2008008531A EC SP088531 A ECSP088531 A EC SP088531A EC SP088531 A ECSP088531 A EC SP088531A
Authority
EC
Ecuador
Prior art keywords
amyloidosis
diseases
amyloid
disorders
compositions
Prior art date
Application number
EC2008008531A
Other languages
English (en)
Inventor
Andrea Pfeifer
Claude Nicolau
Original Assignee
Ac Immune Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37836865&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP088531(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ac Immune Sa filed Critical Ac Immune Sa
Publication of ECSP088531A publication Critical patent/ECSP088531A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/812—Liposome comprising an antibody, antibody fragment, antigen, or other specific or nonspecific immunoeffector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

La presente invención se refiere a métodos y composiciones para uso terapéutico y diagnóstico en el tratamiento de enfermedades y trastornos causados por o asociados con amiloide o proteínas símil amiloide incluso amiloidosis.En particular, la presente invención provee nuevos métodos y composiciones para generar una altamente específica y altamente efectiva respuesta inmune en un organismo, pero particularmente dentro de un animal, particularmente un mamífero o un humano, capaz de prevenir o aliviar amiloidosis, o los síntomas asociados con amiloidosis, un grupo de enfermedades y trastornos asociados con formación de placa amiloide incluso amiloidosis secundaria y amiloidosis relacionada con la edad avanzada incluso, sin limitaciones, trastornos neurológicos tales como enfermedad de Alzheimer (AD), incluso enfermedades o condiciones caracterizados por la pérdida de la capacidad de memoria cognitiva tales como, por ejemplo, deterioro cognitivo leve (MCI).
EC2008008531A 2005-12-12 2008-06-12 Vacuna terapéutica ECSP088531A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05027091 2005-12-12
EP06009098 2006-05-02

Publications (1)

Publication Number Publication Date
ECSP088531A true ECSP088531A (es) 2008-07-30

Family

ID=37836865

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008531A ECSP088531A (es) 2005-12-12 2008-06-12 Vacuna terapéutica

Country Status (23)

Country Link
US (2) US7807175B2 (es)
EP (2) EP2380588B1 (es)
JP (2) JP5249043B2 (es)
KR (2) KR101236611B1 (es)
CN (1) CN101330923B (es)
AR (1) AR058327A1 (es)
AU (1) AU2006326283B2 (es)
BR (1) BRPI0619747B8 (es)
CA (1) CA2633399C (es)
CR (1) CR9994A (es)
DK (1) DK1959991T3 (es)
EC (1) ECSP088531A (es)
ES (2) ES2407429T3 (es)
IL (1) IL191397A (es)
MA (1) MA30252B1 (es)
MY (1) MY181173A (es)
NO (1) NO346055B1 (es)
NZ (1) NZ568384A (es)
RU (2) RU2440824C2 (es)
SG (1) SG172617A1 (es)
TW (1) TWI537000B (es)
WO (1) WO2007068411A2 (es)
ZA (1) ZA200804918B (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
CN101506236B (zh) 2005-11-30 2012-12-12 雅培制药有限公司 抗淀粉样β蛋白的单克隆抗体及其用途
CA2647846C (en) 2006-03-31 2016-06-21 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
CA2670418A1 (en) 2006-11-24 2008-05-29 Ac Immune Sa N-(methyl)-1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimers's
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
EP2481408A3 (en) 2007-03-01 2013-01-09 Probiodrug AG New use of glutaminyl cyclase inhibitors
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
CN106519025B (zh) 2007-09-26 2021-04-23 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
EP2106802A1 (en) 2008-04-02 2009-10-07 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Modified peptides as synthetic vaccines in amyloid-associated disease
CA2721052C (en) 2008-04-11 2023-02-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
EP3936122A1 (en) 2008-11-24 2022-01-12 Massachusetts Institute Of Technology Methods and compositions for localized agent delivery
DK2408807T3 (da) * 2009-03-18 2021-08-09 Ac Immune Sa Fremgangsmåde til terapeutisk anvendelse
UA107571C2 (xx) * 2009-04-03 2015-01-26 Фармацевтична композиція
KR100929372B1 (ko) * 2009-05-22 2009-12-02 고려대학교 산학협력단 아밀로이드 베타 단편을 유효성분으로 포함하는 돌연변이 ｓｏｄ1에 의한 ａｌｓ 예방 및 치료용 조성물
AT508638B1 (de) * 2009-08-21 2011-08-15 Affiris Ag Verwendung von peptiden und polypeptiden zur behandlung und/oder prävention von synukleinopathien
CA2772488C (en) 2009-09-11 2018-04-17 Probiodrug Ag Heterocyclic derivatives as inhibitors of glutaminyl cyclase
EP2311823A1 (en) 2009-10-15 2011-04-20 AC Immune S.A. 2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
NZ602312A (en) 2010-03-10 2014-02-28 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
US20110229556A1 (en) * 2010-03-19 2011-09-22 Massachusetts Institute Of Technology Lipid-coated polymer particles for immune stimulation
US9149432B2 (en) 2010-03-19 2015-10-06 Massachusetts Institute Of Technology Lipid vesicle compositions and methods of use
WO2011115684A2 (en) 2010-03-19 2011-09-22 Massachusetts Institute Of Technology Lipid vesicle compositions and methods of use
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US20110256064A1 (en) 2010-04-16 2011-10-20 Ac Immune, S.A. Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-like Proteins
PH12012502079A1 (en) 2010-04-16 2013-02-11 Ac Immune Sa Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
JP5945532B2 (ja) 2010-04-21 2016-07-05 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
WO2012020124A1 (en) 2010-08-12 2012-02-16 Ac Immune S.A. Vaccine engineering
CN103298833B (zh) 2010-08-14 2015-12-16 Abbvie公司 β淀粉样蛋白结合蛋白
WO2012055933A1 (en) 2010-10-26 2012-05-03 Ac Immune S.A. Liposome-based construct comprising a peptide modified through hydrophobic moieties
BR112013013354A2 (pt) 2010-11-30 2020-10-06 Chugai Seiyaku Kabushiki Kaisha molécula de ligação ao antígeno capaz de se ligar a uma pluralidade de moléculas de antígeno repetidamente
US20120148542A1 (en) 2010-12-10 2012-06-14 Lifeline Scientific, Inc. Machine perfusion with complement inhibitors
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
KR20160005380A (ko) * 2011-09-23 2016-01-15 에이씨 이뮨 에스.에이. 백신 요법
WO2013151762A1 (en) 2012-04-05 2013-10-10 Ac Immune S.A. Humanized tau antibody
RU2661111C2 (ru) 2013-03-15 2018-07-11 Ац Иммуне С.А. Антитела к тау и способы применения
JP7097667B2 (ja) 2013-09-27 2022-07-08 マサチューセッツ インスティテュート オブ テクノロジー 無担体生物活性タンパク質ナノ構造体
US10654807B2 (en) * 2013-12-20 2020-05-19 The University Of Kansas Toll-like receptor 8 agonists
MY181199A (en) 2014-12-19 2020-12-21 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
TWI617580B (zh) 2014-12-19 2018-03-11 中外製藥股份有限公司 抗ｃ５抗體及使用方法
WO2017027843A1 (en) 2015-08-12 2017-02-16 Massachusetts Institute Of Technology Cell surface coupling of nanoparticles
US11472856B2 (en) 2016-06-13 2022-10-18 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
JP6527643B2 (ja) 2016-08-05 2019-06-05 中外製薬株式会社 Ｉｌ−８関連疾患の治療用又は予防用組成物
WO2018081085A1 (en) 2016-10-25 2018-05-03 The Regents Of The University Of California Methods of diagnosis and treatment of alzheimer's disease
US11389465B2 (en) 2017-05-01 2022-07-19 Vanderbilt University Phosphorylated hexaacyl disaccharides (PHADs) for treating or preventing infections
JP7285828B2 (ja) 2017-09-05 2023-06-02 トルク セラピューティクス， インコーポレイテッド 治療用タンパク質組成物ならびにその作製および使用方法
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
TW202333768A (zh) 2017-10-25 2023-09-01 美商健生醫藥公司 Tau胜肽之組成物及其用途
CN108037277A (zh) * 2017-12-07 2018-05-15 中国兽医药品监察所 一种区分牛布鲁氏菌疫苗免疫与自然感染状态的方法
WO2019197414A1 (en) 2018-04-10 2019-10-17 Ac Immune Sa Anti-abeta therapeutic vaccines
CN112165956A (zh) * 2018-04-10 2021-01-01 Ac免疫有限公司 抗Aβ治疗性疫苗
CA3118692A1 (en) 2018-11-06 2020-05-14 Alsatech, Inc. Cell-based gene therapy for neurodegenerative diseases
JOP20210211A1 (ar) 2019-02-08 2023-01-30 Janssen Pharmaceuticals Inc طريقة إعطاء دواء آمنة للقاح ببتيد تاو المفسفر
AU2020262899A1 (en) 2019-04-24 2021-11-18 Ac Immune S.A. Heterologous administration of tau vaccines
SG11202112329RA (en) 2019-05-21 2021-12-30 Ac Immune Sa Anti-abeta vaccine therapy
WO2021207303A1 (en) * 2020-04-07 2021-10-14 Alsatech, Inc. Immune stimulation against coronavirus infections
WO2024156912A1 (en) 2023-01-26 2024-08-02 Ac Immune Sa Anti-abeta vaccine therapy
WO2025109524A1 (en) 2023-11-22 2025-05-30 Ac Immune Sa Assays and methods for assessing vaccine preparations
WO2025196262A1 (en) 2024-03-22 2025-09-25 Ac Immune Sa Immunoassay involving antibodies binding vaccine adjuvants

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4847082A (en) 1987-01-21 1989-07-11 Robert Sabin Method of treatment of Alzheimer's disease using phytic acid
US5262332A (en) * 1989-04-05 1993-11-16 Brigham And Women's Hospital Diagnostic method for Alzheimer's disease: examination of non-neural tissue
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
BR0016022A (pt) * 1999-11-29 2002-08-06 Neurochem Inc Vacina para a prevenção e tratamento da doença de alzheimer e doenças relacionadas ao amilóide
DE10003992A1 (de) * 2000-01-29 2001-08-09 Bosch Gmbh Robert Sensoranordnung
US7067133B2 (en) * 2000-09-06 2006-06-27 Aventis Pharma S.A. Methods and compositions for diseases associated with amyloidosis
EP1203614A1 (de) 2000-11-03 2002-05-08 Polymun Scientific Immunbiologische Forschung GmbH Verfahren und Vorrichtung zur Herstellung von Lipidvesikeln
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
CA2488230C (en) * 2002-04-29 2013-04-09 Yves Claude Nicolau Inositol pyrophosphates, and methods of use thereof
JP2006512417A (ja) 2002-12-24 2006-04-13 ニューロケム （インターナショナル） リミテッド β−アミロイド関連疾患の治療のための治療用製剤
US7521481B2 (en) * 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
EP1629098B1 (en) * 2003-06-02 2009-04-01 Varleigh Limited Complement inhibitors from ticks
WO2005012330A2 (en) * 2003-07-30 2005-02-10 Brigham And Women's Hospital, Inc. AMYLOID β-PEPTIDE AND METHODS OF USE
TW200635608A (en) * 2004-12-15 2006-10-16 Neuralab Ltd Aβ antibodies for use in improving cognition
EP1676859A1 (en) * 2004-12-30 2006-07-05 Pevion Biotech Ltd. Immunogenic compositions of cyclic peptides derived from the beta-amyloid peptide
RU2551782C2 (ru) * 2005-12-12 2015-05-27 Ац Иммуне Са Специфические в отношении амилоида бета (а бета) 1-42 моноклональные антитела, обладающие терапевтическими свойствами

Also Published As

Publication number Publication date
CN101330923A (zh) 2008-12-24
EP1959991A2 (en) 2008-08-27
SG172617A1 (en) 2011-07-28
BRPI0619747B1 (pt) 2019-03-26
KR20080084830A (ko) 2008-09-19
US20090238840A1 (en) 2009-09-24
JP2013126993A (ja) 2013-06-27
EP1959991B1 (en) 2013-03-20
WO2007068411A2 (en) 2007-06-21
US20080267986A1 (en) 2008-10-30
US8603487B2 (en) 2013-12-10
KR20120061049A (ko) 2012-06-12
US7807175B2 (en) 2010-10-05
KR101152557B1 (ko) 2012-09-07
ES2551604T3 (es) 2015-11-20
IL191397A (en) 2016-05-31
WO2007068411A3 (en) 2007-08-23
AU2006326283A1 (en) 2007-06-21
RU2011141308A (ru) 2013-04-20
ES2407429T3 (es) 2013-06-12
AU2006326283B2 (en) 2012-01-19
CN101330923B (zh) 2015-01-07
EP2380588B1 (en) 2015-08-05
AR058327A1 (es) 2008-01-30
RU2440824C2 (ru) 2012-01-27
HK1127486A1 (en) 2009-09-25
EP2380588A1 (en) 2011-10-26
JP2009519915A (ja) 2009-05-21
BRPI0619747B8 (pt) 2021-05-25
ZA200804918B (en) 2011-10-26
RU2008128133A (ru) 2010-01-20
CA2633399C (en) 2016-01-26
NZ568384A (en) 2011-09-30
NO346055B1 (no) 2022-01-24
MA30252B1 (fr) 2009-03-02
CA2633399A1 (en) 2007-06-21
DK1959991T3 (da) 2013-06-17
MY181173A (en) 2020-12-21
NO20082216L (no) 2008-08-22
JP5249043B2 (ja) 2013-07-31
TW200744630A (en) 2007-12-16
CR9994A (es) 2008-09-22
KR101236611B1 (ko) 2013-03-04
TWI537000B (zh) 2016-06-11
BRPI0619747A2 (pt) 2011-10-18

Similar Documents

Publication Publication Date Title
ECSP088531A (es) Vacuna terapéutica
AR058326A1 (es) Anticuerpo monoclonal
MY171300A (en) Pharmaceutical composition
SV2008002511A (es) Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
MX2009003468A (es) Anticuerpo humanizado contra beta amiloide.
UY27003A1 (es) Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer
MX2009013503A (es) Anticuerpo monoclonal anti-amiloide-beta.
PH12013500615A1 (en) Phosphospecific antibodies recognising tau
NI201100100A (es) Moduladores de aril metil benzoquinazolinona alostéricos positivos del receptor m1.
MX354662B (es) Anticuerpos fosfoespecificos que reconocen la tau.
WO2008060364A3 (en) Humani zed antibody against amyloid beta
MY164579A (en) Safe and functional humanized antibodies
MX375282B (es) Pirrolo[2,3-c]piridinas como agentes de formacion de imagenes para ovillos neurofibrilares.
EA200700427A1 (ru) Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний
BRPI0407693A (pt) uso de esteróides para preparação de formulações utilizáveis no tratamento de pessoas sofrendo de distúrbios oculares, bem como formulação assim obtidos
PH12012501882B1 (en) Humanized antibody against amyloid beta
EA201591021A1 (ru) 4-гидрокси-2-метил-5-(пропан-2-илиден)циклогекс-3-энекарбальдегид в профилактике и лечении когнитивных, нейродегенеративных или нейронных заболеваний
UA102368C2 (ru) СПЕЦИФИЧЕСКИЕ В ОТНОШЕНИИ β-АМИЛОИДА 1-42 МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА, КОТОРЫЕ ИМЕЮТ ТЕРАПЕВТИЧЕСКИЕ СВОЙСТВА
WO2008070284A3 (en) Amyloid beta peptides and methods of uses thereof
TH92430B (th) วิธีการรักษาและองค์ประกอบของวัคซีน สำหรับการบำบัดโรคแอมีลอยด์
TH149012A (th) วิธีการรักษาและองค์ประกอบของวัคซีน สำหรับการบำบัดโรคแอมีลอยด์
PE20080455A1 (es) Mirtazapina para el tratamiento de dolor neuropatico
Lim et al. Association of body mass index and cognitive function in Alzheimer's disease and mild cognitive impairment
EP2404612A8 (en) Diagnosis, prophylaxis and therapy of Alzheimer's disease and other neurodementing disorders
Hahm P. 5. a. 005 An open label study of mirtazapine in the treatment of depression with Alzheimer's disease